Desmopressin Acetate

PreclinicalSmall molecule

Teva

Desmopressin Acetate is one of 69 small molecule programs targeting Enuresis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

AdenomaActive, not recruiting

ScoliosisActive, not recruiting

EnuresisPreclinical

Active, not recruiting

AdenomaPreclinical

Active, not recruiting

ScoliosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Adenoma

#DrugCompanyPhaseTrials

Dostinex

Pfizer

Approved

5 2

Orilissa

AbbVie

Approved

1 3

Nolvadex

Duragesic

Octreotide Lar

1 6

Lifyorli (copackaged)

CCorcept Therapeutics

Phase 3

1 7

Celebrex

PPhiladelphia Eye Associates

Phase 3

1 8

Lanreotide PRF

Ipsen

Phase 3

1 9

Olumiant

Eli Lilly

Phase 2

1 10

Antioxidants

IInstitute of Child Health

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Adenoma

NCT04569591

Clinical

Trials by Indication[1]

Enuresis3 trials

Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Completed·MMenoufia University·N/A·NCT06771128·398 enrolled

Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Completed·MMenoufia University·N/A·NCT06772584·90 enrolled

Posterior Tibial Nerve Stimulation Vs Desmopressin In Children With Primary Monosymptomatic Nocturnal Enuresis

Unknown status·—·Phase 4·NCT04545931·80 enrolled

Desmopressin2 trials

Adding Desmopressin to Tamsulosin for Treatment of BPH

Unknown status·MMansoura University·Phase 4·NCT05945420·160 enrolled

Desmopressin Acetate 0.2 mg Tablets, Fasting

Completed· Teva logo

Teva·Phase 1·NCT00835211·48 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Completed· Ferring logo

Ferring·Phase 3·NCT00477490·799 enrolled

Adenoma1 trial

DDAVP for Pituitary Adenoma

Recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT04569591·22 enrolled

Scoliosis1 trial

Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery

Unknown status·LLiu Weifeng·N/A·NCT02084342·60 enrolled

1 more indication

Bleeding Disorder1 trial

Treatment and Management of Women With Bleeding Disorders

Completed·CCenters for Disease Control and Prevention·N/A·NCT00111215·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Desmopressin Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Desmopressin Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Desmopressin Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Teva

Desmopressin Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Enuresis3 trials

Desmopressin2 trials

Efficacy and Safety1 trial

Adenoma1 trial

Scoliosis1 trial

Bleeding Disorder1 trial

References

Drug Info

Quick Facts

Related News